“ Path to Prevention ” Study Accelerates Companies ’ First Foray into Prevention Trials
MJFF continues to lay the groundwork for its novel Phase II Path to Prevention ( P2P ) platform trial , an innovative trial design that tests drugs to prevent Parkinson ’ s in individuals at the earliest biologic stage of the disease .
Platform trials allow multiple treatments to be assessed within the same trial , even all at the same time , a design that helps deliver results quickly and efficiently .
P2P is expected to launch in the United States at the end of 2025 . So far MJFF has selected two novel , experimental therapeutics for P2P , and more are anticipated . Trial participants are being recruited from PPMI , dramatically accelerating recruitment and lowering costs for the companies with promising agents ready for testing .
P2P is the first trial of its kind in PD research and the first study based on the recently published Neuronal Synuclein Disease Integrated Staging System criteria that defines Parkinson ’ s based on its underlying biology .
Another major PD platform trial is in the works in the United Kingdom . Called the Edmond J . Safra Accelerating Clinical Treatments in Parkinson ’ s Disease project and supported by MJFF ’ s long-time partner the Edmond J . Safra Foundation , it will test existing therapies approved for other disease indications , to assess their potential to slow the progression of PD . The study , led by University College London , will enroll participants with laterstage PD including those on stable PD medications .
24